AVANOS MEDICAL, INC.
AVNSNYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $701.2M | $687.8M | $673.3M | $684.1M | $587.0M | $714.8M |
| Operating income | −$61.6M | −$396.2M | $4.2M | $35.5M | −$39.0M | −$48.5M |
| Net income | −$72.9M | −$392.1M | −$61.8M | $50.5M | $6.3M | −$29.0M |
| Total assets | $1.07B | $1.15B | $1.69B | $1.79B | $1.60B | $1.67B |
| Total liabilities | $295.5M | $325.7M | $456.1M | $495.7M | $333.0M | $416.3M |
| Equity | $778.2M | $828.5M | $1.24B | $1.29B | $1.27B | $1.26B |
| EPS (diluted) | $-1.57 | $-8.53 | $-1.32 | $1.07 | $0.13 | $-0.61 |
| Shares out. | 46.0M | 46.2M | 46.6M | 47.3M | 48.0M | 47.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −8.8%
- Net margin
- −10.4%
- Return on equity
- −9.4%
- Return on assets
- −6.8%
- Return on capital (ROCE)
- −6.8%
- Liabilities / assets
- 27.5%
- Debt / equity
- 0.38×
- Book value / share
- $16.92
- Revenue growth (YoY)
- 1.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.17grey zone
- Accruals / assets
- −13.7%clean
- Beneish M-Score
- -3.24normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Altman Z″ in the grey zone
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- T. Rowe Price Investment Management, Inc.Passive (13G)May 7, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Rgm Capital, LlcPassive (13G)Feb 13, 2026
- Dimensional Fund Advisors LpPassive (13G)Jan 21, 2026
- Blackrock, Inc.Passive (13G)Apr 30, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.1M | 1.0 | -5.3% |
| Apr 30, 2026 | 1.2M | 1.0 | -39.6% |
| Apr 15, 2026 | 2.0M | 1.0 | -7.5% |
| Mar 31, 2026 | 2.2M | 4.1 | -7.1% |
| Mar 13, 2026 | 2.3M | 3.6 | -10.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Entered a material agreement · Regulation FD disclosureApr 14, 2026
- Director / officer changeMar 12, 2026
- Entered a material agreement · Other material eventFeb 26, 2026
- Results of operationsFeb 24, 2026
- Regulation FD disclosureJan 13, 2026
- Results of operationsNov 5, 2025
- Director / officer changeOct 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SDFORM SDJun 1, 2026
- PREM14AMay 29, 2026
- SCHEDULE 13G/AMay 15, 2026
- 4FORM 4May 12, 2026
- 4FORM 4May 12, 2026
- 4FORM 4May 12, 2026
- 4FORM 4May 12, 2026
- 4FORM 4May 12, 2026
- SCHEDULE 13G/AMay 7, 2026
- SCHEDULE 13G/AMay 7, 2026
- DEFA14AMay 5, 2026
- 10-QMay 5, 2026
- 8-KMay 5, 2026
- 4FORM 4Apr 24, 2026
- 4FORM 4Apr 24, 2026
Corporate family
Spun off from Kimberly-ClarkKMB · Oct 31, 2014
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.